Background. Early graft dysfunction is a significant complication after renal transplantation and is a marker of adverse outcomes. Although multiple predictors of graft dysfunction have been previously described, the reported prevalence of pulmonary hypertension (pulmonary HTN) in the dialysis population (40-50%), along with biologic and physiologic principles, led us to hypothesize that pulmonary HTN might be an additional risk factor for early graft dysfunction. Methods. We performed a retrospective study that screened all adult renal transplants performed at our institution over a 3-year period and limited the evaluation to those subjects who had an estimated pulmonary artery systolic pressure on a preoperative echocardiogram report (n = 55). The primary outcome of this study was to investigate the impact of pulmonary HTN on early graft dysfunction using a combined endpoint of delayed graft function or slow graft function. Results. Among patients receiving a living donor kidney, early graft dysfunction was not observed regardless of pulmonary HTN status. However, among patients receiving a deceased donor kidney, pulmonary HTN was found to be associated with a significant increased risk of early graft dysfunction (56 vs 11.7%, P = 0.01). Univariate and multivariable logistic regression supported this observation as an independent risk factor beyond potential confounding recipient, donor and graft-based risk factors for early graft dysfunction (P < 0.05). Conclusion. Pulmonary HTN detected on non-invasive imaging prior to renal transplantation appears to be an independent predictor of early graft dysfunction among those patients who receive a deceased donor kidney.
Introduction
The prevalence of pulmonary hypertension (pulmonary HTN) among patients with end-stage renal disease (ESRD) on haemodialysis has been reported to be as high as 40-50% and results in higher mortality rates in affected individuals [1] [2] [3] [4] [5] . Recently, it has been reported that evidence of pretransplant pulmonary HTN as detected using cardiac echocardiography is associated with reduced patient survival after renal transplantation [6] . However, the impact of pulmonary HTN on early graft function after renal transplantation has not been described. Prior research studying the pathogenesis of pulmonary HTN in this patient population has demonstrated a multifactorial aetiology including haemodynamic changes and alterations in vasoactive substances which contribute to increased pulmonary pressures and pulmonary arterial vasoconstriction [4, 5] . It has been hypothesized that similar factors affect the vasculature of renal grafts immediately after transplantation and contribute to the development of early graft dysfunction [7] [8] [9] [10] [11] [12] . Furthermore, it is well recognized that early graft dysfunction results in increased patient morbidity and is also a surrogate marker for decreased long-term graft and patient survival [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Given the potential impact of pulmonary HTN on cardiac function and renal allograft perfusion, as well as similar mechanisms implicated in the pathogenesis of pulmonary HTN and early graft dysfunction, we hypothesized that pulmonary HTN in candidates for renal transplantation may be a predictor of early graft dysfunction.
Materials and methods

Study design and patients
A retrospective cohort of adult renal transplants performed at our institution was reviewed for a 3-year period (January 2003 -August 2006 . A total of 145 transplants (143 patients were included after excluding 2 in-dividuals who were re-transplant recipients) were performed and screened for our inclusion criteria using the electronic medical record (EMR). Baseline characteristic data were acquired on all 143 patients. In order to qualify for the study, the patient had to have a preoperative echocardiogram (resting or stress) that included an adequate evaluation of the tricuspid regurgitant jet with which an estimate of the resting pulmonary artery systolic pressure (PASP) could be obtained. This resulted in 55 study subjects. Of the 88 study subjects who did not meet the inclusion criteria, 39 patients had an echocardiogram but limitations in imaging did not allow for an estimation of the PASP (i.e. inadequate tricuspid regurgitant jet), and the remaining 49 patients did not have a preoperative echocardiogram. No other inclusion or exclusion criteria applied. Outcome data were derived from the EMR. The Dartmouth-Hitchcock Medical Center Institutional Review Board approved this study.
Post-transplant haemodynamics
As per the protocol at our institution, all patients after renal transplantation receive intravenous fluids to attain a central venous pressure of 12-15 cm H 2 O and renal perfusion is confirmed using Doppler ultrasonography. In the immediate post-operative setting, haemodynamics are very closely monitored and blood pressures are tightly controlled with a goal >120/70 but not exceeding 165/95. Patients who remain hypotensive once anti-hypertensive agents have been stopped are started on dopamine in doses not to exceed 7.5 mcg/kg/min in order to maintain systemic blood pressure within this target range.
Echocardiographic data
The most common indication for the echocardiogram was 'preoperative evaluation prior to renal transplant.' All estimates of the PASP were derived from either a resting transthoracic echocardiogram or the resting portion of a dobutamine stress echocardiogram. PASP in response to stress was not routinely recorded and therefore not included in our analysis. If multiple studies were obtained prior to renal transplant, the PASP from the study that occurred within the closest proximity to the transplant was used. The PASP was derived from the modified Bernoulli equation (PASP = 4v 2 + estimated right atrial pressure) which is a validated technique as compared to invasive measurements [25] [26] [27] [28] .
Pulmonary HTN: Definition All study subjects were classified using a binary system based on the estimated PASP which required the application of a clinical 'cut-off' value. If the patient had an estimated PASP ≥35 mm Hg, then pulmonary HTN was deemed to be present. These criteria reflect current institutional practice based upon the literature review of results in patients with ESRD [1] [2] [3] [4] [5] .
Early graft dysfunction: Definitions
Early graft dysfunction was evaluated using the following definitions:
(1) Delayed graft function (DGF): the need for haemodialysis within 1 week after transplantation [22] .
(2) Slow graft function (SGF): non-dialysed patients with a serum Cr ≥ 3 mg/dL on post-transplant day 5 [19] .
The primary outcome of this study was to investigate a possible association between pulmonary HTN and early graft dysfunction using a combined endpoint of DGF or SGF.
Statistical analysis
Comparison of means between two groups for continuous variables was performed using an unpaired t-test. The Fisher's exact test was utilized for binary variables. In addition, we performed a confounding variable analysis, which included previously described risk factors of early graft dysfunction using logistic regression. Logistic regression was used to calculate crude and adjusted odds ratios with 95% CI and P-values. Univariate logistic regression was utilized to determine independent associations. A non-parsimonious multivariable logistic regression model was used to control for potential confounders. Hosmer-Lemeshow goodness-of-fit for the multivariable logistic model was estimated. To evaluate the accuracy of different PASP 'cut-off' values to predict early graft dysfunction, area under receiver operating characteristic (ROC) curves was calculated including 95% CI. Stata 9.0 (College Station, TX) was used for statistical analyses. For all analyses, P-values were two-tailed and <0.05 was considered statistically significant.
Results
Subject characteristics
Of the 143 patients that underwent renal transplant over the 3-year period, 94 patients had a preoperative echocardiogram available for review of which 55 studies included an estimate of the PASP (38% of total). In order to evaluate whether the study subjects who had an echo with a recorded PASP were 'higher risk', we compared the study subset (n = 55) to the excluded patients who had an echo that did not include a measureable PASP at rest (n = 39) and the patients who did not have an echo performed prior to transplantation (n = 49). There was no difference in patient baseline characteristics between the study subjects and the patients with an echo that did not include a measurement of the PASP (Table 1) . When compared to the excluded patients who did not receive a pre-transplant echo, the study group was older in age (53 ± 11 vs 47 ± 13 years, P < 0.05), but there were no other significant differences ( Table 1) . The patient characteristics of the 55 study subjects that met inclusion criteria separated by the presence or absence of pulmonary HTN can be found in Table 2 . The only significant baseline difference between the two groups was the need for haemodialysis prior to transplant which was more prevalent within the pulmonary HTN group (86 vs 50%, P = 0.01). Of the study patients, 71% had an echo performed within 1 year prior to transplantation and 86% had an echo performed within 2 years of transplantation. The average time between the echo and the day of transplant for all patients included in the analysis was 10.9 months. The aetiologies of renal failure among the study subjects are shown in Table 3 .
Prevalence of pulmonary HTN
Among the 55 study subjects, 21 patients (38%) were classified as having pulmonary HTN based on an estimated PASP ≥35 mm Hg. Only one patient in this study carried a previously identified clinical diagnosis of pulmonary HTN per documentation in the EMR.
Pulmonary HTN and early graft dysfunction
The presence of pulmonary HTN on the pre-transplant echocardiogram was observed to be a significant risk factor for early graft dysfunction (43 vs 6%, P = 0.002; Figure 1A ). This effect was confined to patients who received a deceased donor kidney transplant as there were no instances of early graft dysfunction in the recipients of living donor transplants ( Figure 1B) . Among the patients who received a kidney from a deceased donor (n = 33), pulmonary HTN was associated with a significantly increased risk of early graft dysfunction (56 vs 11.7%, P = 0.01; Figure 1B ). In deceased donor allograft recipients, pulmonary HTN is associated with a crude unadjusted odds ratio for early graft dysfunction of 9.64 (P = 0.01). Using the logistic model, when the odds ratio measuring the association between pulmonary HTN and early [29] ], the effect was maintained (Table 4 ). In addition, three separate multivariable analyses were performed (all recipient risk factors combined, all donor and renal graft-specific risk factors combined and all risk factors combined) and each demonstrated a similar result supporting the hypothesis that pulmonary HTN appears to be an independent predictor of early graft dysfunction in this subset of patients. Hosmer-Lemeshow goodness-of-fit for the multivariable logistic model demonstrated no significant difference between the observed and expected values (P = 0.62).
Early graft dysfunction and length of hospitalization at time of transplantation
To further explore the impact of early graft dysfunction on immediate post-transplant outcomes, we evaluated the length of hospitalization at time of transplantation. Patients included in our analysis who developed early graft dysfunction had a significantly longer length of hospital stay as compared to patients with immediate graft function (10.7 vs 5.8 days, P < 0.0001; Figure 2 ).
Sensitivity and specificity of PASP cut-off values for predicting early graft dysfunction
ROC curve analyses were performed to determine the accuracy of different PASP 'cut-off' values to predict early graft dysfunction ( Table 5 ). The cut-off value of ≥35 mm Hg that was used to define our pulmonary HTN group yields a sensitivity of 88% and specificity of 56% in predicting early graft dysfunction. This initial cut-off value was based on prior studies not specific to a renal graft dysfunction endpoint and therefore the sensitivity and specificity may be improved by increasing the cut-off value. A PASP ≥ 40 mm Hg yields a sensitivity of 83% and a specificity of 70%, while an increase to ≥45 mm Hg yields a sensitivity of 75% with a specificity of 80%.
Discussion
Our study suggests that abnormally elevated pulmonary pressures detected by echocardiography in preoperative renal transplant patients appear to be an independent predictor of early graft dysfunction after deceased donor transplantation. The renal transplant patients included in our study had a 38% prevalence of pulmonary HTN which is consistent with prior studies which have reported a 40-50% prevalence among ESRD patients [1] [2] [3] [4] [5] . We demonstrated that the identification of pulmonary HTN during a preoperative echocardiogram was associated with an increased incidence of early graft dysfunction from 12 to 56% after deceased donor transplantation. Logistic regression using covariate and multivariable models supports this finding as independent of previously described risk factors and potential confounders including haemodialysis and the presence of an AVF. Furthermore, as our institution has a protocol in place to maintain strict blood pressure parameters in the perioperative setting, it is unlikely that additional haemodynamic parameters were impacting these results. Finally, though our study did not evaluate the long-term impact of early graft dysfunction on graft and patient survival, we did demonstrate Pulmonary hypertension predicts early graft dysfunctionthat early graft dysfunction was associated with increased perioperative morbidity as evidenced by the significant increase in length of hospitalization at time of renal transplantation. The mechanisms behind the increased prevalence of pulmonary HTN in the ESRD population have been previously examined [1] [2] [3] [4] [5] . Patients with ESRD have been found to have elevated levels of the potent vasoconstrictor endothelin-1 [4] . It has also been demonstrated that ESRD patients with pulmonary HTN have decreased circulating levels of the vasodilator nitric oxide and its metabolites [4] . The increased levels of endothelin-1 and decreased levels of nitric oxide and its metabolites are believed to be a result of endothelial dysfunction resulting in pulmonary vasoconstriction [4] . Simultaneously, the presence of an AVF leads to a high cardiac output state that the noncompliant pulmonary vasculature is unable to compensate for and thus further increases pulmonary pressures [1] . Moreover, patients with ESRD often have significant hypertension and left ventricular diastolic dysfunction that increase pulmonary venous pressures as a contributor to pulmonary HTN. Lastly, the initiation of haemodialysis has been shown to increase pulmonary pressures by mechanisms that have yet to be identified [2] .
The relationship between pulmonary HTN and early graft dysfunction may reflect both haemodynamic changes and alterations in vasoactive substances. Prior research utilizing thermodiffusion probes inserted into the renal cortex of kidney transplant recipients demonstrated that patients who developed DGF had evidence of lower renal microperfusion compared to patients with immediate graft function [7] . The impact of pulmonary HTN on kidney perfusion has not been well described, but there is usually an inverse relationship between the PASP and cardiac output. Invasive studies are needed to clarify to what extent high output from the AVF and low output due to pulmonary HTN contribute to impaired renal perfusion and graft dysfunction. The fact that most patients are initially made hypertensive during the first 24-48 h after transplant to assist with graft perfusion puts further stress on the pulmonary vasculature and perhaps, paradoxically, leads to lower overall cardiac output. Prior studies evaluating the pathogenesis of DGF have demonstrated that the decrease in renal microperfusion is thought to be, in part, the result of increased renovascular resistance from vasoconstriction [8] [9] [10] [11] . The vasoactive substance endothelin has been implicated in the development of ischaemia-reperfusion injury after renal transplantation as it has been previously demonstrated that patients with DGF have high circulating serum levels of endothelin-1 [9] . Furthermore, experimental findings that endothelin-receptor antagonists ameliorated ischaemia-reperfusion injury and early renal dysfunction in rats support the hypothesis that endothelin mediates vasoconstriction which perpetuates post-transplant renal damage [10, 11] . Studies have also demonstrated that nitric oxide helps to maintain vascular relaxation and renal medullary oxygenation, and thus may play an important role in protecting the renal graft against post-transplant vasoconstriction [8, 12] . It is possible that pulmonary HTN in renal transplant candidates may be a marker of patients with altered levels of vasoactive substances which may potentiate post-transplant vasoconstriction and ischaemia-reperfusion injury resulting in early graft dysfunction. In addition, endothelial dysfunction secondary to immunologic factors may also be a contributing factor as prior research has demonstrated a potential role of anti-endothelial cell antibodies in the pathogenesis of both pulmonary HTN associated with connective tissue diseases and renal transplant failure [30, 31] .
Several potential limitations of this study need to be addressed. First, our data demonstrate an association between pulmonary HTN and early graft dysfunction; however, as this is a retrospective study, it is not designed to definitively demonstrate causality. In addition, because of the small sample size of our study, it may have been under powered to detect certain differences. Because of this, the crude and adjusted odds ratios may have been inflated slightly in the risk adjusted analysis. Furthermore, there were no events of early graft dysfunction in the living-related donor group although some patients in that group had an elevated PASP. A larger study might be powered to detect a relationship, but prior research has demonstrated the incidence of early graft dysfunction in living-related donor recipients to be very low [32, 33] .
Second, our study was limited to echocardiographic data. It was not our intent to perform an invasive study, and being retrospective, we were limited to available data. A potential concern is that in the absence of standardization, fluid status at time of echocardiography may have impacted the measured PASP. Although factors such as volume overload and elevated left-sided filling pressures can increase pulmonary pressures, even in the presence of these influences, a measured PASP above a 'threshold level' of 35 mm Hg is considered abnormal and suggests that additional mechanisms are contributing to the reduced compliance of the pulmonary vasculature. In addition, although an invasive study would increase the precision of measured PASP, it is worth noting that the Doppler techniques used on echo can possibly underestimate pressure gradients due to angle dependence, but very rarely over-estimate. Thus, the recorded PASP that were high were likely real findings; however, some patients with pulmonary HTN may have gone undetected. Another concern is possible error in risk stratification as the mean length of time between the echocardiogram and renal transplantation for all patients was 10.9 months. The most common indication for echocardiography in our study patients was 'preoperative testing prior to renal transplantation'. In the absence of cardiac ischaemia or another indication testing generally does not need to be repeated if there is a prolonged time between the initial study and transplantation. Many of our study patients received deceased donor transplants which contributed to the increased time between echo and transplantation as surgery is not scheduled but rather performed on short notice when an organ becomes available. It has previously been reported that non-invasive identification of pulmonary HTN by echocardiography within 3 years of non-cardiac surgery is a marker of increased perioperative morbidity and mortality [34] . In our study, the majority of the patients, 86%, had a preoperative echocardiogram performed within 2 years of transplantation. Thus, we suspect that the identification of patients with an abnormal PASP ≥35 mm Hg at any point in the preoperative setting appears to confer additional risk for the development of early graft dysfunction. Third, there was a concern that our study subjects represented a cohort of patients at higher risk of developing early graft dysfunction, and therefore these results may not be applicable to a more broad population of renal transplant candidates. We addressed this issue by collecting demographic data on all 143 consecutive transplant patients over the 3-year period. Among the patients who had a pretransplant echocardiogram (n = 94), there was no difference in baseline clinical characteristics between patients who had an estimated resting PASP and those that did not. In comparing the study group (echo + reported PASP) to the patients who did not have an echo (n = 49), age of the recipient was the only variable that was significantly different (53 ± 11 vs 47 ± 13 years). We later controlled for age among deceased donor recipients in the logistic regression, and the association between pulmonary HTN and early graft dysfunction was maintained.
This study suggests that pulmonary HTN in renal transplant candidates receiving a deceased donor kidney is associated with an increased risk of early graft dysfunction. A larger prospective study would be needed to confirm these findings as this is a novel observation. Given the sensitivity/specificity analysis, one might consider further evaluation with a right heart catheterization in patients with an estimated PASP ≥40 mm Hg. This would help determine the number of patients who have WHO classification type II pulmonary HTN (secondary to diastolic dysfunction) as compared to other causes. Further research studying the impact of modern medical therapies for the treatment of pulmonary HTN on the development of early graft dysfunction in the context of a randomized controlled trial could be performed to guide clinical practice.
